Cost Management & Benchmarking
Expert articles and analysis related to cost management & benchmarking.
AI Summary — Last 30 Days
In the past 30 days, the focus on cost management and performance benchmarking has intensified among ACOs and other value-based care stakeholders as they prepare for the upcoming 2026 payment landscape. Programs emphasizing predictive cost modeling, such as those highlighted by Persivia, aim to improve the financial performance of ACOs by leveraging data-driven insights. Additionally, the pressures of rising health insurance costs have prompted executives to seek clarity in Medicare Advantage and Medicaid performance, as noted by [Premier](https://premierinc.com/newsroom/blog/the-payer
Related Articles
Efficacy and Cost Savings of Zanubrutinib in High-Risk R/R CLL
Why Cost Transparency Is the First Step Toward Value-Based Healthcare
Why Cost Transparency Is the First Step Toward Value-Based Healthcare  BOSS Publishing
‘A delta in opportunity’: The savings independent ASCs are leaving on the table
While independent physician groups have been busy expanding into the ASC space in recent years, operational gaps have emerged and gone largely unaddressed. According to Pelto Health Partners’ fraction...
Home Care Costs Increase 3% Nationally, Wyoming Most Expensive State
Home Care Costs Increase 3% Nationally, Wyoming Most Expensive State  Home Health Care News
Rising healthcare costs strain health system margins
Systemic challenges are showing few signs of easing in healthcare financial operations. As identified by federal actuaries, increases in the use and intensity of hospital services drove a big recent j...
Paying medical bills leads healthcare cost concerns
Among specific healthcare cost concerns, paying a medical bill leads all others, according to a new survey. Healthcare costs, in general, are a long-standing and rising concern of patients and the pub...
Hospitals Face Increased Costs of Caring for Patients
Hospitals Face Increased Costs of Caring for Patients  American Hospital Association
STAT+: Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial
Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
Government Reports on Healthcare require a Closer Look
Last week, the Federal Government released agency reports that paint a perplexing picture for the health industry entering 2026: Tuesday, The Bureau of Labor Statistics released the EMPLOYMENT COST IN...